Truemeds
PrivateLast Round
Series C
Aug 11, 2025
Est. Valuation
$400M
Total Funding Raised
$112.49M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Truemeds is a healthtech company that operates an e-pharmacy and telehealth platform providing affordable, clinically equivalent generic alternatives to branded medications.
Sector
Healthcare & Life Sciences
Verticals
E-commerce, Telemedicine, D2C Brands, Pharma Supply Chain
Business Model
B2C
Customer Profile
Marketplace Commission, Hardware Sales, Subscription SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Truemeds Comparables
Compare Truemeds with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PharmEasy | 87% | |
| PlatinumRx | 86% | |
| Zeno Health | 85% |
Truemeds Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 11, 2025 | ||||
| Series B | Apr 26, 2022 | ||||
| Series A | Jun 8, 2021 | ||||
| Seed | May 22, 2020 |
Key People
Founding team and executive leadership
Truemeds Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| IAN Group | Series B, Series A |
| Peak XV Partners | Series C |
| Info Edge Ventures | Series B, Series C, Series A, Seed |
| Inception Studio Capital | Series B |
| WestBridge Capital | Series C, Series B |
| Asha Ventures | Series B, Series A |
| Accel | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 1, 2026
Actor Paresh Rawal featured in upcoming campaign.
- Jan 1, 2026
Achieved 3.6x growth in revenue over two years.
Recent news
Latest coverage and updates
- has_revenueSep 10, 2026
Truemeds had revenue of $179M on Sep 1st '25.
- acquiresAug 31, 2026
Truemeds is planning to acquire DealShare.
Truemeds Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Truemeds's valuation, stock price, and market status.
Is Truemeds a public or private company?
Truemeds is a private company.
What is the current stock price of Truemeds?
Truemeds is a private company with no public stock price. No recent secondary market data is available.
How much is Truemeds worth (valuation)?
Truemeds's valuation is estimated at $400.0M based on funding round data.
Can I buy Truemeds stock?
Truemeds shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Truemeds's last funding round?
Truemeds's most recent funding round was Series C on August 11, 2025.
Who are the main investors in Truemeds?
Key investors in Truemeds include Peak XV Partners, WestBridge Capital, Accel.
Will Truemeds IPO soon?
No public IPO plans have been announced for Truemeds.
How can I track Truemeds secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Truemeds's secondary market activity and sign up for updates.